12 are shown in Table 1 ). By contrast, combination of IL-12 with SCF, IL-3, GM-CSF, or G-CSF significantly augmented colony formation in a dose-dependent manner, and the augmentation reached its maximal level at 100 ng/ml of IL-12 in both cell lines (data for 100 ng/ml of IL-12 are shown in Table 1 ). Based on these data, the effect of IL-12 on colony formation by blast progenitors in patient samples was examined at the 100 ng/ml concentration ( Table 1) . IL-12 alone had no significant effect in eight patients and weakly stimulated it in two patients (Nos 1 and 6). In contrast to the modest effect of IL-12 alone, some or all of the combinations of IL-12 with another HGF significantly enhanced colony growth by the cells of every patient. Enhancement of colony formation occurred at similar frequency with any combination of IL-12 and another HGF.
Next, the effect of IL-12 on self-renewal of blast progenitors was determined. Recovery of blast progenitors in suspension culture was assessed as a parameter of self-renewal ability as previously described. 5 Briefly, leukemic cells were cultured in suspension at a concentration of 3 × 10 5 cells/ml (cell lines) or 10 6 cells/ml (patient samples) for 4 days (cell lines) or 7 days (patient samples) in the presence of IL-12 and/or HGFs. After counting the cells, they were transferred into methylcellulose culture with 10% medium conditioned by bladder carcinoma cell line 5637 as a common maximal growth stimulant, and the colonies were counted after 4 to 7 days. Recovery of blast progenitors was calculated by multiplying the number of cells after suspension culture by the plating efficiency in subsequent clonal culture. IL-12, when used alone, exhibited variable effects on patient samples; it suppressed recovery of blast progenitors in specimens from four patients, stimulated it in specimens from three patients, and had no effect on specimens from the remaining three patients ( Table 2) . Titration of IL-12 against patient specimens showed that the inhibition of blast progenitor recovery by IL-12 was dose-dependent, with the maximal effect being obtained at 100 ng/ml (data not shown). However, when IL-12 was used with another HGF, significant growth enhancement was seen in response to some or all combinations in every patient ( Table 2) . Recovery of the blast progenitors in the cell lines was also significantly augmented by IL-12 in most combinations, although IL-12 alone slightly inhibited it, the same as in some patient samples (Table 2 ). Suspension cultures of MO7e cells in the presence of IL-12 contained slightly more dead cells than the cultures in medium alone (34 ± 6% vs 21 ± 2%, P Ͻ 0.05), but there was no significant difference in the OCI/AML1. No apoptotic figures or significant morphological changes indicative of differentiation of leukemic blasts were observed in any patient samples or cell lines in the presence of IL-12.
The above findings indicate that, when used with other HGFs, IL-12 is a potent growth enhancer of blast progenitors in AML, the same as has been shown for normal hematopoietic progenitors. A similar frequency of growth enhancement by IL-12 was seen for both colony formation and self-renewal, although enhancement of one or both of them was not evident in some patients, indicating that IL-12 regulates both clonal growth and self-renewal of blast progenitors. An intriguing finding in this study was that IL-12 inhibited leukemia cell growth in some cases when used alone. NK and T cells, if present in the samples, might exert such an effect by producing cytokines, including IFN-␥, 4 in response to IL-12 stimulation, but they had been removed from patients' samples with monoclonal antibodies, and none should have been present in the cell lines. It has been reported that spontaneous growth of leukemic blasts may be inhibited by certain HGFs, including IL-4, IL-10 and IL-13, via inhibition of the secretion of endogenous HGFs by leukemic blasts or accessory cells. 6 Whether IL-12 possesses such activity needs to be determined.
Despite the in vitro experimental data demonstrating that HGFs stimulate the growth of leukemic progenitors but simultaneously sensitize them to cytotoxic drugs, inconsistent data have been presented in regard to the clinical effects of G-CSF and GM-CSF used in combi- 166 ± 9* 226 ± 12* 198 ± 11* 224 ± 13* 272 ± 12* 230 ± 13 212 ± 8 252 ± 11** 290 ± 14 2 (M1) 206 ± 13 194 ± 4 358 ± 13* 401 ± 14* 311 ± 11* 290 ± 11* 353 ± 4 433 ± 14** 332 ± 6** 320 ± 13** 3 (M2) 132 ± 16 153 ± 16 231 ± 11* 372 ± 15* 412 ± 20* 387 ± 19* 316 ± 14** 456 ± 9** 443 ± 11 423 ± 13 4 (M2) 241 ± 15 235 ± 7 240 ± 6 265 ± 15 294 ± 19* 374 ± 12* 291 ± 5** 288 ± 16 331 ± 16 480 ± 14** 5 (M2) 222 ± 11 222 ± 5 425 ± 9* 379 ± 15* 438 ± 15* 436 ± 8* 450 ± 13 401 ± 4 498 ± 11** 517 ± 14** 6 (M5a) 395 ± 10 425 ± 14* 518 ± 19* 571 ± 15* 607 ± 7* 451 ± 8* 588 ± 21** 600 ± 12 626 ± 14 482 ± 13** 7 (M7) 246 ± 14 231 ± 3 273 ± 11 271 ± 12 280 ± 10* 269 ± 7 303 ± 11** 299 ± 13 306 ± 12** 279 ± 13 8 (RAEB-T) 371 ± 13 369 ± 9 466 ± 4* 462 ± 3* 470 ± 13* 487 ± 7* 526 ± 9** 539 ± 16** 521 ± 4** 540 ± 13** 9 (RAEB-T) 241 ± 3 245 ± 11 511 ± 9* 293 ± 21* 472 ± 19* 506 ± 24* 546 ± 19** 341 ± 10** 463 ± 15 512 ± 20 10 (CML-BC) 191 ± 14 188 ± 13 224 ± 20 237 ± 17* 271 ± 8* 393 ± 12* 262 ± 14 313 ± 20** 268 ± 20 432 ± 7** OCI/AML1 234 ± 15 119 ± 17 † 304 ± 18* 426 ± 15* 701 ± 15* 769 ± 17* 469 ± 8** 716 ± 23** 747 ± 17** 847 ± 19** MO7e 98 ± 8 37± 8 † 475 ± 21* 421 ± 16* 632 ± 15* 184 ± 15* 742 ± 3** 655 ± 13** 765 ± 18** 233 ± 10** nation with chemotherapy to maximize the cytotoxicity of anti-leukemic drugs: administration of GM-CSF consistently shortened the time to neutrophil recovery after chemotherapy, but it did not improve clinical outcome in one study 7 whereas patient survival was significantly prolonged in another study. 8 Future clinical studies should test the efficacy of combinations of two or more HGFs, since HGF combinations have often exhibited more powerful enhancement of drug cytotoxicity in vitro, 5 and their effects might be detectable in vivo. IL-12 could be one of the candidates for use in this strategy of leukemia therapy. Great caution is required, however, when IL-12 is used in leukemia patients without cytotoxic drugs.
Table 2
Recovery of leukemic blast progenitors in suspension culture 
